- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Nasus Pharma Ltd - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 08.10. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.09. | Nasus Pharma stock reiterated at Market Outperform by Citizens | 1 | Investing.com | ||
| 30.09. | Nasus Pharma: Citizens bestätigt "Market Outperform" nach Studienfortschritt | 4 | Investing.com Deutsch | ||
| NASUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 29.09. | Nasus Pharma, Ltd.: Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron | 248 | GlobeNewswire (Europe) | TEL AVIV, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative... ► Artikel lesen | |
| 14.09. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.09. | Nasus Pharma, Ltd.: Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis | 330 | GlobeNewswire (Europe) | Clinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-administration... ► Artikel lesen | |
| 04.09. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.08. | Nasus Pharma Targets Q4 Pivotal Study For Intranasal Epinephrine In $2 Billion Market, With Topline Data Expected Q1 2027 | 1 | pulse2.com | ||
| 19.08. | Nasus Pharma CFO Eyal Rubin to depart in September | 1 | Investing.com | ||
| 19.08. | Nasus Pharma CFO Eyal Rubin to leave | 2 | Seeking Alpha | ||
| 19.08. | Nasus Pharma, Ltd.: Nasus Pharma Announces Transition of Chief Financial Officer | 371 | GlobeNewswire (Europe) | TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development... ► Artikel lesen | |
| 17.08. | Nasus Pharma 1H non-GAAP EPS of -$0.54 | 3 | Seeking Alpha | ||
| 17.08. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 17.08. | Nasus Pharma, Ltd.: Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update | 519 | GlobeNewswire (Europe) | Appointed Pharma Industry Veteran Brendan O'Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, Aug. 17, 2026 (GLOBE... ► Artikel lesen | |
| 28.07. | Nasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman | 1 | RTTNews | ||
| 28.07. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 28.07. | Nasus Pharma names Brendan O'Grady as new CEO | 1 | Investing.com | ||
| 28.07. | Nasus Pharma, Ltd.: Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth | 345 | GlobeNewswire (Europe) | TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of... ► Artikel lesen | |
| 09.06. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EYEPOINT | 0,386 | +1,58 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 34,910 | +1,42 % | Nektar Therapeutics: New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 | Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,575 | -1,20 % | FILANA THERAPEUTICS, INC. - 8-K, Current Report | ||
| IRONWOOD PHARMACEUTICALS | 3,160 | 0,00 % | Ironwood Pharmaceuticals names Tammi Gaskins CEO | ||
| GALECTIN THERAPEUTICS | 2,980 | +1,36 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update | NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 2,180 | +2,11 % | NRx Pharmaceuticals completes manufacturing validation for preservative-free ketamine | ||
| GRACE THERAPEUTICS | 1,915 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 8,030 | -0,50 % | Kazia gains as Guggenheim is latest to initiate at Buy on lead asset | ||
| ELEDON PHARMACEUTICALS | 2,080 | +0,97 % | Eledon Pharmaceuticals, Inc.: Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society | Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus... ► Artikel lesen | |
| INMED PHARMACEUTICALS | 1,140 | -1,72 % | InMed Pharmaceuticals: InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance | Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of... ► Artikel lesen | |
| HERON THERAPEUTICS | 0,277 | +5,41 % | Heron Therapeutics, Inc.: U.S. District Court Issues Decision Regarding CINVANTI Patents | CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court... ► Artikel lesen | |
| INVENTIVA | 3,090 | -1,28 % | INVENTIVA: Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting 2026 | Preclinical data showed that balanced PPARa, PPARd and PPAR? activation by lanifibranor affects complementary pathways across multiple hepatic cell populations involved in fibrosis in MASH pathogenesisPreclinical... ► Artikel lesen | |
| MEDICINOVA | 1,410 | 0,00 % | MediciNova, Inc.: MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) | LA JOLLA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 0,706 | +0,53 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial | MONTREAL and CHARLOTTE, N.C., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
| ANBIO BIOTECHNOLOGY | 3,400 | +0,59 % | Anbio Biotechnology - 6-K, Report of foreign issuer |
NASUS PHARMA LTD gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NASUS PHARMA LTD finden Sie auf Wallstreet Online.